title: What endpoints should be used for clinical studies in acute kidney injury?
authors.affiliation: Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, 604, Scaife Hall, 3550 Terrace Street, Pittsburgh, PA, 15261, USA. kellumja@upmc.edu.
authors.forename: John A
authors.initials: JA
authors.lastname: Kellum
authors.affiliation: Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Zarbock
authors.affiliation: Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
authors.forename: Mitra K
authors.initials: MK
authors.lastname: Nadim
mesh_terms: D058186:Acute Kidney Injury / Q000175:diagnosis / Q000401:mortality / Q000517:prevention & control / Q000628:therapy; D015415:Biomarkers / Q000097:blood / Q000652:urine; D000068456:Clinical Studies as Topic; D018450:Disease Progression; D023381:Endpoint Determination; D006801:Humans; D011788:Quality of Life; D012042:Registries; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers